Liquidia and United Therapeutics could bring new lung indication into legal saga

Liq­uidia said in an SEC fil­ing Wednes­day that it will “ag­gres­sive­ly de­fend” against a po­ten­tial new patent cov­er­ing Unit­ed Ther­a­peu­tics’ tre­pros­tinil for the treat­ment of pul­monary hy­per­ten­sion as­so­ci­at­ed with in­ter­sti­tial lung dis­ease (PH-ILD).

The drug has been at the cen­ter of an on­go­ing court bat­tle be­tween the two com­pa­nies. On Wednes­day, Liq­uidia an­nounced in an SEC fil­ing that Unit­ed Ther­a­peu­tics re­ceived a no­tice of al­lowance re­gard­ing its patent ap­pli­ca­tion gen­er­al­ly cov­er­ing the treat­ment of PH-ILD us­ing an in­haled ver­sion of tre­pros­tinil, mean­ing the US Patent and Trade­mark of­fice has de­ter­mined Unit­ed is en­ti­tled to the patent.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN